{"gui_ge":"10ug","biao_da_su_zhu":"E.coli","biao_qian":"NA","fen_zi_liang":"19.5 KDa","biao_guan_fen_zi_liang":"16 KDa, reducing conditions","xing_tai":"Supplied as a 0.2 μm filtered solution of 40mM Tris-HCl, 300mM NaCl, 5%Trehalose, 5%Mannitol, 0.01%Tween80, 10%Glycerol, pH7.0.","chun_du":"Greater than 95% as determined by reducing SDS-PAGE.","nei_du_su_shui_ping":"Less than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.","chu_cun_fang_fa":"Store at ≤-70°C, stable for 6 months after receipt. \nStore at ≤-70°C, stable for 3 months under sterile conditions after opening. \nPlease minimize freeze-thaw cycles.","yun_shu_tiao_jian":"The product is shipped on dry ice\/polar packs. \nUpon receipt, store it immediately at the temperature listed below. ","bei_jing_shuo_ming":"Human TNFSF10 is a type II transmembrane protein with an intracellular N-terminus and a ‘TNF homology domain’ (THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2\/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells."}